Agree. But by submitting a placeholder when the company clearly could not make it happen, LL stuck a stake in the ground. My opinion, she wants to present and she wants to present at SNO. I should have seen this earlier with ASCO. She may be able to submit a placeholder without LP buying in, but she can’t present anything without NWBO data and approval. The combo study is different, it is an Investigator Initiated Trial. She doesn’t own what is done with the technology, but she does own that data.
No SNO is all on LP and it is a horrible decision, but what do I know. I’ve only launched 10 more drugs than her.
News 
Market Data 
Discover 
AI
